J. Furuse

Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.

Y. Ohkura, H. Ohnishi, Takashi Watanabe, 2014, Oncology reports.

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

Y. Ohkura, H. Ohnishi, Takashi Watanabe, 2014, Cancer Chemotherapy and Pharmacology.

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer

T. Itoi, N. Mizuno, Y. Sakata, 2017, British Journal of Cancer.

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

M. Miyazaki, J. Furuse, M. Nagino, 2010, British Journal of Cancer.

Continuous comprehensive geriatric assessment could predict the prognosis in elderly cancer patients

M. Ando, K. Miyajima, T. Akechi, 2013 .